GlassScriptPhysician profile
Jeffrey Hilburn
NPI 1962409805
$3,724.24
in general payments reported to CMS, 2019-2025
28 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $449 · 2021: $686 · 2022: $619 · 2023: $342 · 2024: $530 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,344.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $974.42 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $597.04 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $452.30 | 2019-2025 | |
| Genzyme Corporation | $349.50 | 2019-2022 | |
| Eisai INC. | $212.76 | 2021-2023 | |
| Amgen INC. | $146.72 | 2021-2024 | Uplizna |
| Harmony Biosciences LLC | $142.31 | 2021-2025 | |
| Livanova USA, INC. | $121.30 | 2020-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Argenx US, INC. | $117.31 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $81.56 | 2022-2024 | Tysabri, Vumerity |
| Pfizer INC. | $80.39 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $47.62 | 2021-2024 | Onpattro |
| Janssen Pharmaceuticals, INC | $47.60 | 2022 | |
| Allergan, INC. | $36.39 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $36.30 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $30.38 | 2021 | |
| Inspire Medical Systems, INC. | $28.61 | 2023 | Inspire |
| Cycle Pharmaceuticals INC | $26.45 | 2025 | Tascenso Odt |
| Amneal Pharmaceuticals LLC | $24.56 | 2024 | Rytary |
| Tanabe Pharma America, INC. | $23.99 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.77 | 2019 | |
| Jazz Pharmaceuticals INC. | $22.87 | 2020 | |
| Catalyst Pharmaceuticals, INC. | $21.80 | 2024 | |
| Sumitomo Pharma America, INC. | $20.43 | 2023 | Aptiom |
| Ipsen Biopharmaceuticals, INC | $17.63 | 2025 | Dysport |
| E.R. Squibb & Sons, L.L.C. | $15.47 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.67 | 2020 | |
| Almatica Pharma LLC | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hilburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.